AR098059A1 - INTRAVAGINAL USE OF THE 18-METHYL-15b, 16b-METILEN-19-NOR-20-ESPIROX-4-EN-3-ONAS, INTRAVAGINAL RINGS THAT INCLUDE 18-METHYL-15b, 16b-METHYLEN-19-NOR-20- ESPIROX-4-EN-3-ONAS AND ITS USE IN ANTI-CONCEPT - Google Patents

INTRAVAGINAL USE OF THE 18-METHYL-15b, 16b-METILEN-19-NOR-20-ESPIROX-4-EN-3-ONAS, INTRAVAGINAL RINGS THAT INCLUDE 18-METHYL-15b, 16b-METHYLEN-19-NOR-20- ESPIROX-4-EN-3-ONAS AND ITS USE IN ANTI-CONCEPT

Info

Publication number
AR098059A1
AR098059A1 ARP140103862A ARP140103862A AR098059A1 AR 098059 A1 AR098059 A1 AR 098059A1 AR P140103862 A ARP140103862 A AR P140103862A AR P140103862 A ARP140103862 A AR P140103862A AR 098059 A1 AR098059 A1 AR 098059A1
Authority
AR
Argentina
Prior art keywords
methyl
espirox
onas
intravaginal
metilen
Prior art date
Application number
ARP140103862A
Other languages
Spanish (es)
Inventor
Dr Rse Lars
Dr Schmees Norbert
Dr Lindenthal Bernhard
Dr Nubbemeyer Reinhard
Jukarainen Harri
Valo Tuula
Pihlaja Jyrki
Dr Holmberg Svante
Dr Muhn Hans
Peter - Dr Prelle Katja
Maria Dr Hofmann Birte
Dr Fuhrmann Ulrike
M Dr Fels Lder
Original Assignee
Bayer Pharma AG
Bayer Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Oy filed Critical Bayer Pharma AG
Publication of AR098059A1 publication Critical patent/AR098059A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

Reivindicación 1: Uso intravaginal caracterizado porque es de las 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas de la fórmula general (1), donde tanto R⁶ como R⁷ son átomos de hidrógeno, o bien juntos son un grupo a-metileno. Anillo intravaginal que comprende una 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-ona de la fórmula general (1). Reivindicación 3: Anillo intravaginal caracterizado porque comprende una 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-ona de la fórmula general (1) donde tanto R⁶ como R⁷ son átomos de hidrógeno, o bien juntos son un grupo a-metileno.Claim 1: Intravaginal use characterized in that it is 18-methyl-15b, 16b-methylene-19-nor-20-spirox-4-en-3-ones of the general formula (1), where both R⁶ and R⁷ are atoms of hydrogen, or together they are an a-methylene group. Intravaginal ring comprising an 18-methyl-15b, 16b-methylene-19-nor-20-spirox-4-en-3-one of the general formula (1). Claim 3: Intravaginal ring characterized in that it comprises an 18-methyl-15b, 16b-methylene-19-nor-20-spirox-4-en-3-one of the general formula (1) wherein both R⁶ and R⁷ are hydrogen atoms , or together they are an a-methylene group.

ARP140103862A 2013-10-17 2014-10-17 INTRAVAGINAL USE OF THE 18-METHYL-15b, 16b-METILEN-19-NOR-20-ESPIROX-4-EN-3-ONAS, INTRAVAGINAL RINGS THAT INCLUDE 18-METHYL-15b, 16b-METHYLEN-19-NOR-20- ESPIROX-4-EN-3-ONAS AND ITS USE IN ANTI-CONCEPT AR098059A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361892398P 2013-10-17 2013-10-17

Publications (1)

Publication Number Publication Date
AR098059A1 true AR098059A1 (en) 2016-04-27

Family

ID=51842499

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103862A AR098059A1 (en) 2013-10-17 2014-10-17 INTRAVAGINAL USE OF THE 18-METHYL-15b, 16b-METILEN-19-NOR-20-ESPIROX-4-EN-3-ONAS, INTRAVAGINAL RINGS THAT INCLUDE 18-METHYL-15b, 16b-METHYLEN-19-NOR-20- ESPIROX-4-EN-3-ONAS AND ITS USE IN ANTI-CONCEPT

Country Status (4)

Country Link
AR (1) AR098059A1 (en)
TW (1) TW201605457A (en)
UY (1) UY35789A (en)
WO (1) WO2015055789A1 (en)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3920805A (en) 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
US4215691A (en) 1978-10-11 1980-08-05 Alza Corporation Vaginal contraceptive system made from block copolymer
US4292965A (en) 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
DE3040978A1 (en) 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen VAGINAL RING
FR2618329B1 (en) 1987-07-22 1997-03-28 Dow Corning Sa METHOD OF MANUFACTURING A RING CAPABLE OF ENSURING THE RELEASE OF A THERAPEUTIC AGENT, AND RING MANUFACTURED BY THIS METHOD
FI90627C (en) 1992-07-31 1994-03-10 Leiras Oy Apparatus for providing a medicine rod with a jacket
PH30867A (en) 1992-07-31 1997-12-09 Leiras Oy Method and equipment for installing a medicine capsule on a support.
US5869081A (en) 1996-06-28 1999-02-09 The Population Council Progesterone vaginal ring for treatment of infertility
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
IL123813A0 (en) 1997-04-11 1998-10-30 Akzo Nobel Nv Drug delivery system for two or more active substances
DE102006030416A1 (en) 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-methyl-19-nor-androst-4-ene-17,17-spiroethers (18-methyl-19-nor-20-spirox-4-en-3-ones) and pharmaceutical compositions containing them
DE102008026793A1 (en) * 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-ring-substituted pregn-4-ene-21,17-carbolactones, as well as pharmaceutical compositions containing them
FI121000B (en) 2008-11-19 2010-06-15 Bayer Schering Pharma Oy Intravaginal delivery system and method for its preparation
TW201350122A (en) * 2012-04-23 2013-12-16 Bayer Pharma AG Intrauterine use of 18-methyl-15 β , 16 β -methylene-19-nor-20-spirox-4-en-3-ones, intrauterine systems comprising 18-methyl-15 β , 16 β -methylene-19-nor-20-spirox-4-en-3-ones, and use thereof in contraception and gynaecological treatmen

Also Published As

Publication number Publication date
WO2015055789A1 (en) 2015-04-23
TW201605457A (en) 2016-02-16
UY35789A (en) 2015-05-29

Similar Documents

Publication Publication Date Title
MY191169A (en) Anti-fcrh5 antibodies
DOP2019000180A (en) INHIBITORS OF TGFß1 ISOFORM-SPECIFIC CONTEXT-PERMISIVES AND USE OF THE SAME
CR20150462A (en) ERK INHIBITORS AND THEIR USES
UY34566A (en) 1,4? DIHYDROPIRIMIDINES 4.4? DISUSTITUTED AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
CL2016001432A1 (en) New anti-dpep3 antibodies and methods of use
UY34278A (en) NEW NOXEDINE DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF DISEASES
CR20150519A (en) COMPOUNDS OF 1, 3-OXAZIN-2-AMINA FUSED WITH PERFORMED CILOPROPILE AS BETA-SECRETASE INHIBITORS AND METHODS OF USE
EA201691194A1 (en) RHC STIMULATORS
DOP2015000219A (en) HETEROARILO COMPOUNDS AND ITS USES
CO7151531A2 (en) Antibodies and immunoconjugates against ly6e and methods of use
BR112015023215A2 (en) enhanced cognitive supplements
CL2015002562A1 (en) Anti-b7-h4 antibodies and immunoconjugates
UY34764A (en) DERIVATIVES OF 2,2-DIFLUOROPROPIONAMIDE OF BARDOXOLONE METHOD, POLYMODIC FORMS AND ITS METHODS OF USE
BR112016006319A2 (en) irak inhibitors and uses thereof
UY34536A (en) NUCLEOSIDS REPLACED, NUCLEOTID AND ANALOG OF THE SAME
CR20150247A (en) ANTIHEMAGLUTININE ANTIBODIES AND METHODS OF USE
UY34763A (en) INHIBITORS OF THE PLAQUETARY AGGREGATION
ECSP13012786A (en) ANTI-PCSK9 ANTIBODIES AND METHODS OF USE
UY34721A (en) ANTI-HLA-B * 27 ANTIBODIES AND USES OF THESE.
UY34342A (en) ? DERIVATIVES OF PIRROLOPIRIMIDINA AND PURINA ?.
UY34605A (en) ARILALQUYLOXYPIRIMIDINE DERIVATIVES AND AGRICULTURAL INSECTICIDES THAT INCLUDE SUCH DERIVATIVES AS ACTIVE PRINCIPLES, AND THE METHOD OF USE OF THE SAME
AR091959A1 (en) SYNTHETIC SUSTAINABLE AGENTS AND MONODISPERSE SUSTAINABLE AGENTS AND METHODS FOR THE ELABORATION OF THE SAME
CR20160270A (en) ANTI-TAU ANTIBODIES (pS422) HUMANIZED AND USED METHODS
UY34271A (en) ANTI-TIE2 ANTIBODIES AND USES OF THE SAME
UY34539A (en) HETEROARILOS AND USES OF THE SAME

Legal Events

Date Code Title Description
FB Suspension of granting procedure